Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Low-vision aids and vision rehabilitation
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Low-vision aids and vision rehabilitation

2 evidence topics · 2 sources

Stargardt disease: patient-care guidance: low-vision care

“Vision aids, vision rehabilitation” (opens the source at this quote in a new tab)

Management of ABCA4 retinopathy: review

“Update on the Management of ABCA4 Retinopathy (Stargardt Disease)” (opens the source at this quote in a new tab)
“Supportive care remains a foundational component in the management of ABCA4 retinopathy” (opens the source at this quote in a new tab)